Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Intrathecal Analgesia in Laparoscopic Nissen Fundoplication.

NCT07629323 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2026-03-10
Last updated
2026-06-05

Condition(s) studied

Perioperative Pain ManagementGastreoesophageal Reflux Disease

Investigational drug(s) / intervention(s)

Fentanyl Intrathecal 20ugNOL-guided intravenous morphine analgesiaIntrathecal Morphine 100ug →

Fentanyl Intrathecal 20ug: Intrathecal Fentanyl

NOL-guided intravenous morphine analgesia: NOL guided intravenous morphine analgesia

Intrathecal Morphine 100ug: Norhine 100ug intrathecal

Study summary

Patients planned for laparoscopic Nissen fundoplication or robotic- assisted laparoscopic surgery will receive either intrathecal morphine, intrathecal fentanyl or iv morphine (control).

Perioperative total opioid consumption, Postoperative Pain Numeric Rating scale, grade of nausea and time in the postoperative ward are compared. Total grade of patient satisfaction (0-10) as well as total hospital length are also compared.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: All patients scheduled for laparoscopic fundoplicatio surgery \- Exclusion Criteria: - * Age \< 18 years * Chronic pain problems or abuse. * Pregnancy * Exclusion ciriteria for spinal anesthesia.

Primary outcome measure(s)

  • Three different treatments of pain during during laparoscopic and/or robotic assisted laparoscopic Nissen fundoplication. — From enrollment to the end of treatment - usually the day after surgery.
    1. Primary outcome measure: Total perioperative opioid consumtion converted to morphine equivalents. 2. Secondary outcome measure: Patient pain scores (NRS 1-10) when arriving at the PACU, when leaving the PACU and the highest pain score in the PACU.
  • Postoperative pain assessed using the Visual Analogue Scale (VAS) upon arrival to the post-anesthesia care unit (PACU), maximum VAS score in PACU, and at discharge to ward/home/patient hotel. — From inclusion to the day after surgery.
    Secondary outcomes: 1. Total intraoperative opioid dose and postoperative opioid and other analgesic requirements during the first 24 hours. 2. Postoperative nausea (0-10 scale). 3. Need for antiemetic treatment postoperatively. Length of hospital stay (days). 8\. Need for urinary catheterization (indwelling catheter or intermittent catheterization) within 24 hours postoperatively or at discharge.
  • "Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0" — "From enrollment to the end of treatment at the day after surgery
    Paricipants arriving at the PACU with pain score according to the Visual Analogue Scale (VAS) \> 3

Trial sites (1)

FacilityCityRegionStatus
Department of Anesthesia & Intensive Care, Central Hospital of Karlstad Karlstad Värmland County
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07629323 on ClinicalTrials.gov ↗ ← All trials in Sweden